Publications by authors named "Jan A Burger"

Claim this Profile
F
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
Jan A Burger, Paul M Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD.
Ekaterina Kim, Shih-Shih Chen, Mariela Sivina, Hyunsoo Hwang, Xuelin Huang, Jan A Burger

Blood· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mathematical multi-compartment modeling of chronic lymphocytic leukemia cell kinetics under ibrutinib.
Melanie Schulz, Sanne Bleser, Manouk Groels, Dragan Bošnački, Jan A Burger

iScience· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the Number of Polygenic Diseases Among Six Mutually Exclusive Entities of Non-Tumors and Cancer.
C I Edvard Smith, Jan A Burger, Rula Zain

Int J Mol Sci· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.
Philipp M Roessner, Isabelle Seufert, Vicente Chapaprieta, Ruparoshni Jayabalan, Hannah Briesch, Jan A Burger

Blood· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
Firas M Safa, Terri Rasmussen, Lorena Fontan, Min Xia, Ari Melnick, Jan A Burger

Haematologica· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Paul J Hampel, Mahesh Swaminathan, Kerry A Rogers, Erin M Parry, Jan A Burger

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age-matched general population: A pooled post hoc analysis.
Paolo Ghia, Carolyn Owen, John N Allan, Jacqueline C Barrientos, Paul M Barr, Jan A Burger

Hemasphere· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Lymphocytic Leukemia: Disease Biology.
Stefan Koehrer, Jan A Burger

Acta Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation.
Laura M Roccograndi, Alexandra R Lovell, Alessandra Ferrajoli, Philip A Thompson, Jan A Burger

Leuk Lymphoma· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
Max J Gordon, Jade E Jones, Binsah George, Christine Peterson, Jan A Burger

Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Membranous nephropathy in chronic lymphocytic leukemia responsive to ibrutinib: A case report.
Anna-Eve Turcotte, William F Glass, Jamie S Lin, Jan A Burger

Leuk Res Rep· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language Summary.
Paul M Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A Burger

Future Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.
Jennifer A Woyach, Paul M Barr, Thomas J Kipps, Jacqueline C Barrientos, Inhye E Ahn, Jan A Burger

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular map of chronic lymphocytic leukemia and its impact on outcome.
Binyamin A Knisbacher, Ziao Lin, Cynthia K Hahn, Ferran Nadeu, Martí Duran-Ferrer, Jan A Burger

Nat Genet· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
Nicholas J Short, Gautam Borthakur, Naveen Pemmaraju, Courtney D Dinardo, Tapan M Kadia, Jan A Burger

Leuk Lymphoma· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
Jan A Burger, Tadeusz Robak, Fatih Demirkan, Osnat Bairey, Carol Moreno

Leuk Lymphoma· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Paul M Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A Burger

Blood Adv· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.
Uri Rozovski, Ivo Veletic, David M Harris, Ping Li, Zhiming Liu, Jan A Burger

J Immunol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures.
Alicia M Vaca, Nikolaos Ioannou, Mariela Sivina, Elisavet Vlachonikola, Karen Clise-Dwyer, Jan A Burger

Leukemia· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences.
Anneke D van Dijk, Ti'ara L Griffen, Yihua H Qiu, Fieke W Hoff, Endurance Toro, Jan A Burger

Leukemia· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
Gavin Cull, Jan A Burger, Stephen Opat, David Gottlieb, Emma Verner

Br J Haematol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia.
Andrea N Mazzarello, Eva Gentner-Göbel, Marcus Dühren-von Minden, Tatyana N Tarasenko, Antonella Nicolò, Jan A Burger

J Clin Invest· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.
Mariela Sivina, Ekaterina Kim, William G Wierda, Alessandra Ferrajoli, Nitin Jain, Jan A Burger

Blood· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CLL cells are moved by the MARCKS brothers.
Jan A Burger

Blood· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis